Roche: positive data for Vabysmo in minorities

(CercleFinance.com) - Roche reports positive initial results at one year from the single-arm, open-label Phase IV ELEVATUM study evaluating Vabysmo for the treatment of diabetic macular edema (DME) in ethnic minorities often under-represented in clinical trials.


Presented at the American Academy of Ophthalmology (AAO) in Chicago on 18 October, the efficacy and safety of this study involving 124 participants in the United States proved to be in line with data from Phase III studies.

The study showed a clinically significant improvement in vision and a reduction in retinal fluid in people with DME treated with Vabysmo who identified themselves as Afro-American, Black, Hispanic and Latino.

These racial and ethnic groups are disproportionately affected by diabetes and have a higher risk of developing DME, one of the leading causes of vision loss, the Swiss healthcare group said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.